Drugs in Dev. Oncology
IND Enabling
Japan 
Lead Product(s) : PD-29875
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
PeptiDream Announces Radiopharmaceutical Program for Gastric Cancer Diagnosis, Treatment
Details : PD-29875 is a novel first-in-class highly-selective macrocyclic peptide-radioisotope conjugate against Claudin 18.2 expressed in a variety of solid tumors, including gastric cancer, pancreatic cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 12, 2024
Lead Product(s) : PD-29875
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Radgocitabine,Venetoclax
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Delta-Fly Pharma Authorized to Conduct Phase I/II of DFP-10917 Combined with Venetoclax
Details : DFP-10917 (radgocitabine) is a DNA polymerase inhibitor small molecule drug candidate which is being evaluated in combination with venetoclax for the treatment of acute myeloid leukemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 08, 2024
Lead Product(s) : Radgocitabine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Radgocitabine,Venetoclax
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Delta-Fly Pharma Submits Phase I/II Protocol of DFP-10917 and Venetoclax for AML to FDA
Details : DFP-10917 (radgocitabine) is a DNA polymerase inhibitor small molecule drug candidate which is being evaluated in combination with venetoclax for the treatment of acute myeloid leukemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 11, 2024
Lead Product(s) : Radgocitabine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Datopotamab Deruxtecan,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the agreement between Daiichi Sankyo and Merck & Co., Inc., Kenilworth, NJ., USA, Daiichi Sankyo will lead TROPION-Lung08, a global phase 3 trial that will evaluate datopotamab deruxtecan in combination with KEYTRUDA compared to KEYTRU...
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
October 25, 2021
Lead Product(s) : Datopotamab Deruxtecan,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : CTX-177
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Ono Pharmaceutical
Deal Size : $509.7 million
Deal Type : Collaboration
Details : Under the terms of the agreement, Chordia will grant exclusive rights to develop, manufacture and commercialize CTX-177 and other related compounds globally.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 15, 2020
Lead Product(s) : CTX-177
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Ono Pharmaceutical
Deal Size : $509.7 million
Deal Type : Collaboration
Reset All
